TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor

  Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be

  Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1

SEATTLE, Oct. 04, 2024 — Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of

  TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and

  Kineta will be trading under the symbol “KANT” on OTC Pink Kineta will continue to pursue strategic alternatives as

  Effective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for

  TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety